NCT05752175已完成2 期
A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of WPV01 in Patients With Mild/Moderate COVID-19 Infection
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 80
- 试验地点
- 1
- 主要终点
- Changes in viral load
研究概览
简要总结
A randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of WPV01 in patients with mild/moderate COVID-19 infection
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants ≥18 years of age when signing ICF;
- •Initial onset at least 1 of 11 COVID-19 symptoms within 48 hours before randomization;
- •Within three days before randomization, the RT-PCR test of specimens such as nasal and pharyngeal swabs must be positive for SARS-CoV-2 or the rapid antigen test must be positive, and also the patiets should meet the diagnostic criteria for mild or moderate cases as defined in the Diagnosis and Treatment Protocol for COVID-19 (Trial Version 10) issued by the National Health Commission of China;
- •Fertile participants must agree to take effective contraceptive measures;
- •Participants who understand and agree to comply with planned study procedures，voluntarily participate in this clinical trial and sign an informed consent form.
排除标准
- •Known allergy to any ingredient in the study treatment drug;
- •Patients who meet the diagnostic criteria for severe or critical cases of COVID-19 as defined in the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 10) issued by the National Health Commission of China at the time of randomization;
- •Obvious abnormal liver function (ALT or AST ≥ 3ULN, or total bilirubin ≥1.5ULN);
- •On dialysis or combined with moderate to severe kidney injury;
- •Patients with compromised immune system;
- •Patients with acute exacerbation of chronic respiratory disease at screening, including bronchial asthma, chronic obstructive pulmonary disease;
- •Patients with suspected or confirmed concurrent active systemic infection other than COVID-19 at screening;
- •Any comorbidity requiring surgery within 14 days prior to study entry, or that is considered life threatening within 30 days prior to study entry, as determined by the investigator;
- •Has received or is expected to receive COVID-19 monoclonal antibody or convalescent COVID-19 plasma during study treatment;
- •Has received treatment with antivirals against SARS-CoV-2 within 14 days prior to randomization;
- •Has received any novel coronavirus infection vaccine within 1 week prior to randomization;
- •Current or expected use of strong CYP3A4 inducers, inhibitors or medications that are highly dependent on CYP3A4 for clearance;
- •Difficulty swallowing or a history of gastrointestinal disorders that severely interfere with drug absorption;
- •BMI≥30 kg/m2;
- •Pregnant, lactating women or those with a positive pregnancy test;
- •Previous administration with any investigational drug within 3 months before the study drug administration;
- •Patients who are judged by the investigator to be unsuitable to participate in this study.
研究组 & 干预措施
WPV01
Experimental
干预措施: WPV01 (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Changes in viral load
时间窗: Baseline through Day 7
Change of viral load compared to the baseline
次要结局
- Change in the score of each COVID-19 symptom(Baseline through Day 14)
- Change in the total score of COVID-19 symptoms(Baseline through Day 14)
- Change of EuroQol Questionnaire - 5 Dimension (EQ-5D)(Baseline through Day 14)
- percentage of patients who reached the sustained clinical recovery of COVID-19 symptoms in every visit(Baseline through Day 14)
- progression of COVID-19 infection(Baseline through Day 14)
- Time to the first negative SARS CoV-2 test result(Baseline through Day 14)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
A Study to Find the Best Dose of HS-10384 to Treat Vasomotor Symptoms in Postmenopausal WomenVasomotor SymptomsNCT06393673Hansoh BioMedical R&D Company195
已完成
2 期
Efficacy and Safety Study of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH)Pulmonary Arterial HypertensionNCT01553721Dong-A ST Co., Ltd.63
终止
2 期
Efficacy and Safety Study of SUNPG1622Active Ankylosing Spondylitis or Non-Radiographic Axial SpondyloarthritisNCT02980705Sun Pharmaceutical Industries Limited180
Unknown
2 期
A Study to Evaluate the Efficacy and Safety of DXP604 in Patients With Mild to Moderate COVID-19COVID-19NCT05381519Wuhan Institute of Biological Products Co., Ltd50
Unknown
2 期
A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Exosomes Overexpressing CD24 to Prevent Clinical Deterioration in Patients With Moderate or Severe COVID-19 InfectionCOVID-19 DiseaseNCT04969172Eli Sprecher, MD155